MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia, Marie‐France Hamou, Nicolas de Tribolet, Michael Weller, Johan M. Kros, Johannes Andreas Hainfellner, Warren P. Mason, Luigi Mariani, Jacoline E. C. Bromberg, Peter Hau, R.O. Mirimanoff, John Gregory Cairncross, Robert Charles Janzer, Roger Stupp
New England Journal of Medicine · 2005 · 7,609 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Hegi, M. E., Diserens, A., Gorlia, T., Hamou, M., Tribolet, N. de, Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W. P., Mariani, L., Bromberg, J. E. C., Hau, P., Mirimanoff, R., Cairncross, J. G., Janzer, R. C., & Stupp, R. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352(10), 997–1003. https://doi.org/10.1056/nejmoa043331
In text: (Hegi et al., 2005)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: Epigenetic silencing of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating agents. METHODS: We tested the relationship between MGMT silencing in the tumor and the survival of patients who were enrolled in a randomized trial comparing radiotherapy alone with radiotherapy combined with concomitant and adjuvant treatment with temozolomide. The methylation status of the MGMT promoter was determined by methylation-specific polymerase-chain-reaction analysis. RESULTS: The MGMT promoter was methylated in 45 percent of 206 assessable cases. Irrespective of treatment, MGMT promoter methylation was an independent favorable prognostic factor (P<0.001 by the log-rank test; hazard ratio, 0.45; 95 percent confidence interval, 0.32 to 0.61). Among patients whose tumor contained a methylated MGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy; their median survival was 21.7 months (95 percent confidence interval, 17.4 to 30.4), as compared with 15.3 months (95 percent confidence interval, 13.0 to 20.9) among those who were assigned to only radiotherapy (P=0.007 by the log-rank test). In the absence of methylation of the MGMT promoter, there was a smaller and statistically insignificant difference in survival between the treatment groups. CONCLUSIONS: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.
Related papers
Metadata from OpenAlex (CC0). Citations are generated from the published record.